Halozyme is transforming from a royalty-based business focused on ENHANZE technology into a broader subcutaneous drug delivery platform. The company reported a 52% increase in royalty revenue for fiscal year 2025, reaching $867.8 million, and projects 30-35% royalty growth with adjusted EBITDA between $1.125 billion and $1.205 billion for 2026. Recent acquisitions and partnerships with companies like Vertex and Takeda enhance its intellectual property and position Halozyme as a comprehensive biologic delivery solutions provider. Despite strong growth and high margins, Halozyme trades at a notable valuation discount, suggesting potential investment value.
Confo Therapeutics announced encouraging preclinical data for CFTX-2034, a novel antibody targeting post-bariatric hypoglycemia (PBH), a condition with no approved treatments. The data showed CFTX-2034 effectively controls insulin and GLP-1 secretion...
Pardee Resources Company announced an agreement to sell about 2,465 acres of surface and mineral property in West Virginia for approximately $57 million, priced at $23,000 per acre. The sale depends on certain contingencies and normal closing conditi...
Western Digital's stock surged to a new 52-week high following a bullish upgrade by Morgan Stanley analyst Erik Woodring, who raised his price target from $488 to $650. The optimism is driven by expected 30%+ year-over-year growth in nearline enterpr...
Nuvei announced it will acquire Payoneer in an all-cash deal valued at $2.75 billion, offering Payoneer shareholders $7.40 per share. The merger aims to create a global commerce platform supporting businesses in over 190 countries, enhancing payment ...
Eli Lilly announced that its Phase 3 BRUIN CLL-322 trial showed adding Jaypirca (pirtobrutinib) to venetoclax and rituximab significantly improved progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or...
